» Articles » PMID: 15193340

A "mitochondrial Cascade Hypothesis" for Sporadic Alzheimer's Disease

Overview
Journal Med Hypotheses
Specialty General Medicine
Date 2004 Jun 15
PMID 15193340
Citations 319
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) includes etiologically heterogeneous disorders characterized by senile or presenile dementia, extracellular amyloid protein aggregations containing an insoluble amyloid precursor protein derivative, and intracytoplasmic tau protein aggregations. Recent studies also show excess neuronal aneuploidy, programmed cell death (PCD), and mitochondrial dysfunction. The leading AD molecular paradigm, the "amyloid cascade hypothesis", is based on studies of rare autosomal dominant variants and does not specify what initiates the common late-onset, sporadic form. We propose for late-onset, sporadic AD a "mitochondrial cascade hypothesis" that comprehensively reconciles seemingly disparate histopathologic and pathophysiologic features. In our model, the inherited, gene-determined make-up of an individual's electron transport chain sets basal rates of reactive oxygen species (ROS) production, which determines the pace at which acquired mitochondrial damage accumulates. Oxidative mitochondrial DNA, RNA, lipid, and protein damage amplifies ROS production and triggers three events: (1) a reset response in which cells respond to elevated ROS by generating the beta-sheet protein, beta amyloid, which further perturbs mitochondrial function, (2) a removal response in which compromised cells are purged via PCD mechanisms, and (3) a replace response in which neuronal progenitors unsuccessfully attempt to re-enter the cell cycle, with resultant aneuploidy, tau phosphorylation, and neurofibrillary tangle formation. In addition to defining a role for aging in AD pathogenesis, the mitochondrial cascade hypothesis also allows and accounts for histopathologic overlap between the sporadic, late-onset and autosomal dominant, early onset forms of the disease.

Citing Articles

Gut microbiome synthesizes important core metabolites to prevent cognitive decline and mitigate onset and progression of Alzheimer's disease.

Al-Abbas N, Shaer N J Alzheimers Dis Rep. 2025; 8(1):1705-1721.

PMID: 40034366 PMC: 11863740. DOI: 10.1177/25424823241309024.


Exploring the Link Between Periodontitis and Alzheimer's Disease-Could a Nanoparticulate Vaccine Break It?.

Ferreira da Silva A, Gomes A, Goncalves L, Fernandes A, Almeida A Pharmaceutics. 2025; 17(2).

PMID: 40006510 PMC: 11858903. DOI: 10.3390/pharmaceutics17020141.


Mitochondrial Alterations, Oxidative Stress, and Therapeutic Implications in Alzheimer's Disease: A Narrative Review.

Spina E, Ferrari R, Pellegrini E, Colombo M, Poloni T, Guaita A Cells. 2025; 14(3).

PMID: 39937020 PMC: 11817193. DOI: 10.3390/cells14030229.


Bidirectional Mendelian Randomization Analysis of the Association Between Mitochondrial Proteins and Neurodegenerative Diseases.

Wang F, Jing Z, Wang Q, Li M, Lu B, Huo A Brain Behav. 2025; 15(1):e70283.

PMID: 39831399 PMC: 11744296. DOI: 10.1002/brb3.70283.


Sodium Thiosulfate: An Innovative Multi-Target Repurposed Treatment Strategy for Late-Onset Alzheimer's Disease.

Hayden M, Tyagi N Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770582 PMC: 11676759. DOI: 10.3390/ph17121741.